William Lewis Sells 10,699 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $166.97, for a total value of $1,786,412.03. Following the transaction, the chief executive officer directly owned 303,911 shares of the company’s stock, valued at $50,744,019.67. The trade was a 3.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Insmed Price Performance

Shares of NASDAQ:INSM traded up $8.29 during trading on Friday, reaching $174.84. The stock had a trading volume of 19,055,575 shares, compared to its average volume of 2,791,147. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75. The stock has a market cap of $37.29 billion, a PE ratio of -28.25 and a beta of 1.01. The business has a fifty day moving average price of $187.41 and a 200-day moving average price of $142.30.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. During the same quarter in the previous year, the business posted ($1.27) EPS. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. On average, equities analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC raised its position in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Kingsview Wealth Management LLC increased its stake in shares of Insmed by 2.7% during the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after buying an additional 60 shares during the period. Choreo LLC raised its holdings in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares in the last quarter. Spire Wealth Management lifted its stake in Insmed by 11.5% in the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 80 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 81 shares in the last quarter.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed acquired a phase‑2‑ready monoclonal antibody to broaden its respiratory / immunology pipeline, which management presents as a near‑term program to offset the brensocatib setback. Press release: Clinical and business update
• Positive Sentiment: Certain Wall Street firms maintained “Buy” ratings even after lowering targets, leaving institutional support intact and providing potential technical support for the stock. (See coverage noting maintained buys and revised targets.) Analyst coverage summary
• Neutral Sentiment: Large call‑option buying was reported (6,582 calls), signaling speculative or hedged interest that can amplify intraday moves but does not by itself change fundamentals.
• Neutral Sentiment: Trading in INSM was temporarily halted when the company disclosed the trial outcome, a normal market‑structure response that concentrated the initial price move when trading resumed.
• Negative Sentiment: The core negative: the Phase 2b BiRCh study of brensocatib in CRSsNP failed to meet primary and secondary efficacy endpoints in both dose arms, and Insmed has discontinued the CRSsNP program — a clear hit to near‑term growth expectations for that drug. Reuters: Scraps development after mid‑stage failure
• Negative Sentiment: Market reaction was sharp: shares plunged in after‑hours/extended trading and across media coverage, erasing much of the recent rally as investors re‑price the company without the CRSsNP indication. Barron’s: What sparked the selloff
• Negative Sentiment: Analysts trimmed longer‑range estimates and price targets (HC Wainwright cut FY2028 EPS, TD Cowen and Guggenheim lowered targets), which reduces near‑term upside consensus and could weigh on sentiment until the new asset is de‑risked. MarketBeat: analyst note summary

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on INSM shares. TD Cowen decreased their target price on shares of Insmed from $269.00 to $241.00 and set a “buy” rating on the stock in a research note on Thursday. The Goldman Sachs Group boosted their price objective on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research note on Monday. Wells Fargo & Company set a $195.00 target price on Insmed in a research note on Thursday. Rothschild & Co Redburn initiated coverage on Insmed in a report on Thursday, December 4th. They set a “buy” rating and a $263.00 price target on the stock. Finally, Mizuho set a $212.00 price objective on shares of Insmed in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Insmed presently has an average rating of “Moderate Buy” and an average target price of $205.41.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.